The company has not filed an annual or quarterly report since its Q1 FY2017 10-Q, filed May 10, 2017. Its latest SEC filing is a EFFECT from Dec 11, 2017.
10-Q for Q1 FY2017, filed May 10, 2017
The sections below describe the company as of the FY2016 annual report.
Developed drug and device candidates for people with eye disorders, plus mobile health tools to monitor retinal disease progression.
10-K for FY2016, filed Mar 15, 2017
Revenue came from collaboration agreements with Otsuka, with development-work revenue tied to services as they were performed; agreements could also include license fees, research funding, milestone payments, product sales or royalties.
10-K for FY2016, filed Mar 15, 2017One of our business strategies is to enter into collaboration agreements with pharmaceutical companies for the development and…View ↗
Revenue recognized for the years ended December 31, 2016, 2015, and 2014 consists entirely of amounts derived from our collaboration…View ↗
Revenue from development efforts is recognized as services are incurred by third-parties. Revenue earned by full-time or part-time salaried…View ↗
$7.6M
10-K for FY2016, filed Mar 15, 2017
$7.6M ↗
Pharmaceutical companies partnered on drug development; Otsuka was the source of all reported revenue through collaboration agreements.
10-K for FY2016, filed Mar 15, 2017
No. It lost $34.5M in .
10-K for FY2016, filed Mar 15, 2017
Shrank. Revenue fell 84% in 4 years, from $46.4M in to $7.6M in , about 36% a year.
Competes with Alkeus Pharmaceuticals and Sanofi
10-K for FY2016, filed Mar 15, 2017The pharmaceutical, biotechnology and medical device industries are intensely competitive, and our product candidates, if commercialized…View ↗
Loading...
